Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $697.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 6.02% year-over-year to $697.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (up 2.96% YoY), and the FY2025 full-year result was $668.2 million, down 10.28% from the prior year.
• Liabilities and Shareholders Equity advanced to $697.5 million in Q1 2026, from $668.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $744.7 million in Q4 2024 to a low of $239.9 million in Q1 2023.
• A 5-year average of $503.4 million and a median of $603.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 31.13% in 2023 and surged 162.35% in 2024, its largest moves.
• Tracing PTGX's Liabilities and Shareholders Equity over 5 years: stood at $247.9 million in 2022, then soared by 44.38% to $358.0 million in 2023, then jumped by 108.05% to $744.7 million in 2024, then slipped by 10.28% to $668.2 million in 2025, then gained by 4.38% to $697.5 million in 2026.
• Business Quant data shows PTGX's Liabilities and Shareholders Equity at $697.5 million in Q1 2026, $668.2 million in Q4 2025, and $701.7 million in Q3 2025.